CDKN2A and central nervous system cancer: Genetic alterations, such as PDGFB amplification, the homozygous loss of Cyclin Dependent Kinase Inhibitor 2A (CDKN2A), and coding for p16INK4A and p14ARF, show high frequency in human glioma [4].